# OnCo record furmonertinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/furmonertinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "furmonertinib" ;
  schema:name "Furmonertinib"@en ;
  schema:description "Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial."@en ;
  schema:url <https://onco.cc/drugs/furmonertinib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Furmonertinib> ;
  schema:citation <https://www.allist.com.cn/>, <https://doi.org/10.1016/S2213-2600(22)00168-0>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule third-generation EGFR TKI" ;
  schema:alternateName "Ivesa" ;
  onco:approval "China 2021: EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy", "China 2022: First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/allist/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/egfr-mutation-subtypes/> ;
  onco:trials <https://onco.cc/trials/furlong/>, <https://onco.cc/trials/nct05607550/>, <https://onco.cc/trials/nct07185997/>, <https://onco.cc/trials/nct06962865/>, <https://onco.cc/trials/nct07622186/>, <https://onco.cc/trials/nct05994131/>, <https://onco.cc/trials/nct04853342/>, <https://onco.cc/trials/nct05466149/>, <https://onco.cc/trials/nct06970639/> .